BIOMAT Database Logo BIOMAT Database Logo

Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. 1997

M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Department of Internal Medicine, Akita University School of Medicine, Japan.

A controlled trial comparing combination therapy with ofloxacin (OFLX) and interferon (IFN) versus IFN monotherapy was conducted in patients with chronic hepatitis C who failed IFN therapy. Twenty patients were assigned randomly to two groups. Equal doses of recombinant IFN alpha-2b were administered to each group for 24 weeks. For the IFN plus OFLX group, OFLX was administered for 12 weeks at a daily dose of 600 mg. Levels of hepatitis C virus RNA declined significantly from the first month after the start of IFN treatment compared with those before administration in both groups. Serum alanine aminotransferase levels were significantly lower in the IFN plus OFLX group at two and six months after the start of treatment than levels in the IFN group. The fraction of subjects whose levels of serum ALT normalized was also higher in the IFN plus OFLX group. Larger clinical trials should be undertaken.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study.
November 1996, Journal of gastroenterology and hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.
October 1999, Clinical biochemistry,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.
August 1998, Journal of hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon.
May 2000, Journal of gastroenterology and hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Combination therapy with interferon alpha and beta to chronic hepatitis C.
January 2003, Oncology reports,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C.
February 2006, Hepatology research : the official journal of the Japan Society of Hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.
June 1998, Journal of hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.
April 2003, Journal of hepatology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
January 2002, Journal of gastroenterology,
M Komatsu, and T Ishii, and T Ono, and T Hoshino, and T Kuramitsu, and T Goto, and T Fujii, and I Toyoshima, and M Chiba, and O Masamune
Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial.
September 1999, Antiviral research,
Copied contents to your clipboard!